公开(公告)号：EP3253871A1

公开(公告)日：2017-12-13

申请号：EP16708801.2

申请日：2016-02-04

申请人： Bristol-Myers Squibb Company ,  Roche Innovation Center Copenhagen A/S

发明人： HAGEDORN, Peter ,  OLSON, Richard E. ,  HØG, Anja Mølhart ,  JENSEN, Marianne Lerbech ,  LI, Dong ,  NIELSEN, Niels Fisker

IPC分类号： C12N15/11 ,  C12N15/113 ,  A61K31/712

CPC分类号： C12N15/113 ,  C12N15/111 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/3231 ,  C12N2310/341 ,  C12N2310/343 ,  C12N2310/346 ,  C12N2310/351

摘要： The present invention relates to LNA oligomers having two flanks, wherein one or both flanks comprise alternating LNA and DNA nucleosides.

公开(公告)号：EP3954993A1

公开(公告)日：2022-02-16

申请号：EP21186197.6

申请日：2016-02-04

申请人： Bristol-Myers Squibb Company ,  Roche Innovation Center Copenhagen A/S

发明人： OLSON, Richard E. ,  CACACE, Angela, M. ,  HAGEDORN, Peter ,  HØG, Anja Mølhart ,  NIELSEN, Niels, Fisker ,  LI, Dong ,  BROWN, Jeffrey, M. ,  MERCER, Stephen, E. ,  JENSEN, Marianne, Lerbech

IPC分类号： G01N33/50

摘要： The present disclosure provides methods of using a calcium oscillation assay and/or a sequence score calculation to identify a molecule that is safe for administration. The disclosure also includes a method of selecting or identifying a molecule having tolerable in vivo neurotoxicity using a calcium oscillation assay, a sequence score method, an in vivo tolerability assay, or any combination thereof.

公开(公告)号：EP3254104A1

公开(公告)日：2017-12-13

申请号：EP16709167.7

申请日：2016-02-04

申请人： Bristol-Myers Squibb Company ,  Roche Innovation Center Copenhagen A/S

发明人： OLSON, Richard E. ,  CACACE, Angela, M. ,  HAGEDORN, Peter ,  HØG, Anja Mølhart ,  NIELSEN, Niels, Fisker ,  LI, Dong ,  BROWN, Jeffrey, M. ,  MERCER, Stephen, E. ,  JENSEN, Marianne, Lerbech

IPC分类号： G01N33/50

CPC分类号： G01N33/5058 ,  G01N33/5014

摘要： The present disclosure provides methods of using a calcium oscillation assay and/or a sequence score calculation to identify a molecule that is safe for administration. The disclosure also includes a method of selecting or identifying a molecule having tolerable in vivo neurotoxicity using a calcium oscillation assay, a sequence score method, an in vivo tolerability assay, or any combination thereof.